39977-73-6

Basic information

• Product Name: quinoline-3-carbaldehyde oxime
• Synonyms: quinoline-3-carbaldehyde oxime;3-Quinolinecarbaldehyde oxime;3-QUINOLINECARBOXALDEHYDE,OXIME
• CAS NO: 39977-73-6
• Molecular Formula: C₁₀H₈N₂O
• Molecular Weight: 172.18332
• EINECS: 254-727-5
• Mol File: 39977-73-6.mol

Chemical Properties

• Boiling Point: 336.2°Cat760mmHg
• Flash Point: 157.2°C
• Appearance: /
• Density: 1.2g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.623
• CAS DataBase Reference: quinoline-3-carbaldehyde oxime(CAS DataBase Reference)
• NIST Chemistry Reference: quinoline-3-carbaldehyde oxime(39977-73-6)
• EPA Substance Registry System: quinoline-3-carbaldehyde oxime(39977-73-6)

Safety Data

• Hazardous Substances Data: 39977-73-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H8N2O/c13-12-7-8-5-9-3-1-2-4-10(9)11-6-8/h1-7,13H/b12-7+

Upstream product

• 13669-42-6 3-quinolylcarboxaldehyde 

Downstream Products

• 612-58-8 3-methylquinoline 
• 7521-70-2 3-(aminomethyl)quinoline 

Relevant articles and documents

Identification of histone deacetylase inhibitors with (arylidene)aminoxy scaffold active in uveal melanoma cell lines

Uveal melanoma (UM) represents an aggressive type of cancer and currently, there is no effective treatment for this metastatic disease. In the last years, histone deacetylase inhibitors (HDACIs) have been studied as a possible therapeutic treatment for UM, alone or in association with other chemotherapeutic agents. Here we synthesised a series of new HDACIs based on the SAHA scaffold bearing an (arylidene)aminoxy moiety. Their HDAC inhibitory activity was evaluated on isolated human HDAC1, 3, 6, and 8 by fluorometric assay and their binding mode in the catalytic site of HDACs was studied by molecular docking. The most promising hit was the quinoline derivative VS13, a nanomolar inhibitor of HDAC6, which exhibited a good antiproliferative effect on UM cell lines at micromolar concentration and a capability to modify the mRNA levels of HDAC target genes similar to that of SAHA.

SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel spiro-oxadiazoline compounds that are suitable as agonists or partial agonists of a7-nAChR, and pharmaceutical compositions of the same, methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering a spiro-oxadiazoline cx7-nAChR agonist or partial agonist, to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

6-O-substituted erythromycin derivatives having improved gastrointestinal tolerance

Compounds having formula (I) are useful for treating bacterial infections while avoiding the concomitant liability of gastrointestinal intolerance. Compositions containing the compounds and methods of treatment using the compounds are also disclosed.

Method of treating tuberculosis

Macrolide and ketolides, and compositions containing the same, useful in the treatment of tuberculosis are disclosed. Methods of treating tuberculosis using the macrolides and ketolides, and compositions containing the same, also are disclosed.